We must utilise this opportunity to be more forthright about the fact that without animal research, the bio-pharmaceutical sector cannot continue to innovate new treatments.
We welcome the support of everyone who has signed the Declaration on openness on animal research so far – well known charities, funders, and academia, along with some of the biggest pharmaceutical companies in the world. The signing of this Declaration marks the beginning of a much larger process, with all areas of the life sciences community coming together to reaffirm the importance of our work and recommit to openness in animal research.
ABPI Press Office
Tel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7808 641810 or +44 (0) 7850 312064
Notes to editors
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.